Market closed
Qiagen/$QGEN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Qiagen
Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
Ticker
$QGEN
Sector
NON_CLASSIFIED
Trading on
NYSE
Industry
Biotechnology & Drugs
Headquarters
Venlo, Netherlands
Employees
5,967
Website
Qiagen Metrics
BasicAdvanced
$9.6B
28.35
$1.53
0.42
-
Price and volume
Market cap
$9.6B
Beta
0.42
52-week high
$47.74
52-week low
$34.77
Average daily volume
21M
Financial strength
Current ratio
1.99
Quick ratio
1.621
Long term debt to equity
24.209
Total debt to equity
39.65
Enterprise value to free cash flow
26.181
Management effectiveness
Return on assets (TTM)
5.50%
Return on equity (TTM)
9.38%
Return on investment (TTM)
6.60%
Valuation
Price to earnings (TTM)
28.354
Price to revenue (TTM)
4.883
Price to book
2.515
Price to tangible book (TTM)
11.919
Price to free cash flow (TTM)
32.351
Growth
Revenue change (TTM)
-8.23%
Earnings per share change (TTM)
-19.52%
3-year revenue growth (CAGR)
1.66%
3-year earnings per share growth (CAGR)
-1.18%
What the Analysts think about Qiagen
Analyst Ratings
Majority rating from 19 analysts.
Qiagen Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$509M
7.00%
Net income
$98M
25.45%
Profit margin
19.17%
17.25%
Qiagen Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$0.53
$0.52
$0.55
$0.46
-
Expected
$0.52
$0.50
$0.55
$0.44
$0.52
Surprise
1.14%
3.47%
0.26%
4.83%
-
Qiagen News
AllArticlesVideos
QIAGEN Advances Cancer Genomic Profiling With New Products and Partnership Updates at AACR Annual Meeting 2025
Business Wire·2 days ago
QIAGEN Advancing Plans to Launch Three New Sample Preparation Instruments by 2026 to Improve Lab Automation
Business Wire·1 week ago
QIAGEN N.V. to Release Results for Q1 2025 and Hold Webcast
Business Wire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Qiagen stock?
Qiagen (QGEN) has a market cap of $9.6B as of April 24, 2025.
What is the P/E ratio for Qiagen stock?
The price to earnings (P/E) ratio for Qiagen (QGEN) stock is 28.35 as of April 24, 2025.
Does Qiagen stock pay dividends?
No, Qiagen (QGEN) stock does not pay dividends to its shareholders as of April 24, 2025.
When is the next Qiagen dividend payment date?
Qiagen (QGEN) stock does not pay dividends to its shareholders.
What is the beta indicator for Qiagen?
Qiagen (QGEN) has a beta rating of 0.42. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.